Iovance Biotherapeutics (IOVA) Non-Current Deffered Revenue (2017 - 2018)
Iovance Biotherapeutics (IOVA) posted quarterly Non-Current Deffered Revenue of $230000.0 for Q4 2018, down 22.56% year-over-year from $297000.0 in Q4 2017, and down 22.56% quarter-over-quarter from $297000.0 in Q4 2017.
Iovance Biotherapeutics (IOVA) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Non-Current Deffered Revenue for 2 consecutive years, with $230000.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Non-Current Deffered Revenue fell 22.56% year-over-year to $230000.0; the TTM figure through Dec 2018 stood at $230000.0 (down 22.56% YoY), while the FY2018 annual figure was $230000.0, down 22.56% from the prior year.
- Non-Current Deffered Revenue declined to $230000.0 in Q4 2018 per IOVA's latest filing, from $297000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $297000.0 in Q4 2017 and bottomed at $230000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 230,000.00 |
| Dec 31, 2017 | 297,000.00 |